| Literature DB >> 30646195 |
Mikael Norman1,2,3, Ann Hellström4, Boubou Hallberg1,2, Agneta Wallin5, Pelle Gustafson6, Kristina Tornqvist7, Stellan Håkansson3,8, Gerd Holmström9.
Abstract
Importance: Retinopathy of prematurity (ROP) can cause severe visual disability even in high-resource settings. A better understanding of the prevalence and processes leading to ROP-induced severe visual impairment may help health care professionals design preventive measures.Entities:
Mesh:
Year: 2019 PMID: 30646195 PMCID: PMC6324320 DOI: 10.1001/jamanetworkopen.2018.6801
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Figure. Flowchart of Participants
EXPRESS indicates Extremely Preterm Infants in Sweden Study; ICD-10, International Classification of Diseases, Tenth Revision; ROP, retinopathy of prematurity; SNQ, Swedish Neonatal Quality Registry; SWEDROP, Swedish National Register for Retinopathy of Prematurity.
Adherence to National Guidelines and Best Practice in the Neonatal Period Among 17 Children Who Developed Severe Visual Disability Due to ROP
| Key Performance Indicator | No./Total No. (%) |
|---|---|
| Documentation in neonatal unit records | |
| Documentation of ROP stage only | 11/14 (79) |
| Documentation included zone or type | 3/14 (21) |
| ROP screenings documented in neonatal record | 6/13 (46) |
| ROP treatment documented in neonatal record | 6/13 (46) |
| If transfer to other hospitals, ROP screenings and treatment clearly documented | 4/11 (36) |
| Screening | |
| For infants with GA at birth ≥27 wk, first screening examination at 5 wk postnatal age | 1/2 (50) |
| If GA at birth <27 wk, first screen no later than 31 wk postmenstrual age | 11/14 (79) |
| Screening exams repeated >2 weeks apart | 3/13 (23) |
| Postponed screening exams | 5/14 (36) |
| If transferred to other hospital, timely screening without interruption | 4/11 (36) |
| Diagnosis and treatment | |
| Missed indication for treatment | 6/17 (35) |
| Timely treatment (within 72 h of diagnosis) | 7/15 (47) |
| Aggressive ROP treated within 48 h | 5/12 (42) |
| First treatment with <1500 laser photocoagulation applications | 6/12 (50) |
| Postoperative retinal examination within 5-7 d | 10/15 (67) |
| Additional information on treatment | |
| Second laser treatment | 12/14 (86) |
| Anti–vascular endothelial growth factor administered | 2/17 (12) |
| Vitrectomy or encircling band | 10/17 (59) |
Abbreviations: GA, gestational age; ROP, retinopathy of prematurity.
Some data missing or nonapplicable (3 children evaluated using available registry and database information but medical records were unavailable).
Perinatal Characteristics of 17 Children in Sweden With Severe Visual Disability due to ROP, 2004 to 2015
| Maternal Characteristics | No. (%) |
|---|---|
| Maternal age, mean (SD) [range], y | 30.5 (6.8) [20-41] |
| Primiparous mother | 8 (47) |
| Pregnancy and delivery | |
| Diabetes in pregnancy | 0 |
| Multiple pregnancy | 1 (6) |
| Preeclampsia | 2 (12) |
| Any antenatal corticosteroids | 16 (94) |
| Delivery at level III unit | 12 (71) |
| Cesarean delivery | 7 (41) |
| Duration of gestation, mean (SD) [range], wk | 24.8 (2.7) [22-33] |
| Infant characteristics | |
| Boys | 10 (59) |
| Birth weight, mean (SD) [range], g | 756 (341) [454-1900] |
| Small for gestational age | 3 (18) |
| Neonatal morbidity | |
| Intraventricular hemorrhage grade 3-4 or cystic periventricular leukomalacia | 2 (12) |
| Patent ductus arteriosus, treated | 14 (83) |
| Patent ductus arteriosus surgery | 9 (53) |
| Septicemia | 10 (59) |
| Necrotizing enterocolitis | 0 |
| Bronchopulmonary dysplasia | 16 (94) |
| Hospital transfers | |
| ≥2 Transfers between hospitals | 11 (65) |
| ROP stages and treatment | |
| ROP stage 5 both eyes | 9 (53) |
| ROP stage 5 one eye | 2 (12) |
| ROP stage 4 one or two eyes | 6 (35) |
| Laser applications for first treatment, No. | |
| Mean (SD) | 1340 (547) |
| Median (range) | 1324 (203-2048) |
| Laser applications for second treatment, No. | |
| Mean (SD) | 617 (422) |
| Median (range) | 430 (172-1151) |
Abbreviation: ROP, retinopathy of prematurity.
Nonadherence to Guidelines and Avoidable Patient Injury
| Type of Noncompliance to Key Performance Indicator | Infants, No. | ||
|---|---|---|---|
| Total | Visual Disability Possibly Avoidable | Visual Disability Avoidable | |
| Untimely screening (never done, started too late, or postponed several times) | 5 | 0 | 3 |
| Missed diagnosis, staging, or grading | 2 | 0 | 2 |
| Treatment untimely or suboptimal | 10 | 6 | 1 |
One infant with both untimely screening and suboptimal treatment.
Survey on Structure for ROP Screening, Diagnosis, and Treatment in 24 Swedish Ophthalmology Departments
| Infrastructure and Capacity | No. (%) |
|---|---|
| Very preterm infants screened in hospital annually, No. | |
| <10 | 3 (12) |
| 10-50 | 15 (62) |
| >50 | 6 (25) |
| Retinal camera | |
| Available in the facility | 14 (58) |
| Used for screening | 5 (21) |
| Photographs transferred to center of excellence | 3 (12) |
| Documentation | |
| Results of ROP screenings documented in both ophthalmology and neonatal medical record | 7 (29) |
| Guidelines | |
| Written guidelines for screening, diagnosis, and treatment of ROP | 23 (94) |
| Written standard for notifying ROP surgeon | 9 (38) |
| Written standard for reporting ROP status when patient is transferred to other hospital | 5 (21) |
| Ophthalmologists for ROP screenings in department, No. | |
| 1-2 | 7 (29) |
| 3-4 | 14 (58) |
| ≥5 | 3 (12) |
| ROP screening examinations performed per ophthalmologist annually, No. | |
| <25 | 5 (21) |
| 25-50 | 12 (50) |
| >50 | 7 (29) |
| Treatment of ROP performed | |
| At the facility | 6 (25) |
| At regional center | 10 (42) |
| Outside region | 8 (33) |
| Laser or anti–vascular endothelial growth factor treatments performed at facility annually, No. | |
| 0 | 18 (75) |
| 1-4 | 1 (4) |
| 5-10 | 3 (12) |
| >10 | 2 (8) |
Abbreviation: ROP, retinopathy of prematurity.